Clenbuterol to Target DUX4 in FSHD — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Clenbuterol to Target DUX4 in FSHD — Stella

Home/Muscular Dystrophy, Facioscapulohumeral/

View on ClinicalTrials.gov

Recruiting

Back to Muscular Dystrophy, Facioscapulohumeral trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(3 sites)

United States

University of Kansas Medical Center, Kansas City, Kansas

University of Rochester Medical Center, Rochester, New York

University of Washington, Seattle, Washington

Key details

Phase

Early testing

Sponsor

Jeffrey Statland

Collaborators

University of Washington, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Enrollment target

~30 participants

Started

June 2025

Primary completion

February 2028

Age range

18 Years – 75 Years

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.